Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.
- DOI
- 10.1186/s12885-022-10316-w
- Published
- 2022 Nov 24
- Container
- BMC cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-022-10316-w,
title = {Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.},
author = {Sato MT and Ida A and Kanda Y and Takano K and Ohbayashi M and Kohyama N and Morita J and Fuji K and Sasaki H and Ogawa Y and Kogo M},
year = {2022},
journal = {BMC cancer},
doi = {10.1186/s12885-022-10316-w},
url = {https://doi.org/10.1186/s12885-022-10316-w}
}RIS
TY - JOUR TI - Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma. AU - Sato MT AU - Ida A AU - Kanda Y AU - Takano K AU - Ohbayashi M AU - Kohyama N AU - Morita J AU - Fuji K AU - Sasaki H AU - Ogawa Y AU - Kogo M PY - 2022 JO - BMC cancer DO - 10.1186/s12885-022-10316-w UR - https://doi.org/10.1186/s12885-022-10316-w ER -
APA
MT, S., A, I., Y, K., K, T., M, O., N, K., J, M., K, F., H, S., Y, O., & M, K. (2022). Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.. BMC cancer. https://doi.org/10.1186/s12885-022-10316-w
Source records
- pubmed · retrieved 2026-09-27T00:46:13.179Z